WO2013111014A3 - Méthodes et compositions destinées au traitement de la perte neuronale dans des maladies intestinales inflammatoires - Google Patents

Méthodes et compositions destinées au traitement de la perte neuronale dans des maladies intestinales inflammatoires Download PDF

Info

Publication number
WO2013111014A3
WO2013111014A3 PCT/IB2013/000463 IB2013000463W WO2013111014A3 WO 2013111014 A3 WO2013111014 A3 WO 2013111014A3 IB 2013000463 W IB2013000463 W IB 2013000463W WO 2013111014 A3 WO2013111014 A3 WO 2013111014A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory bowel
compositions
methods
bowel disease
neuron loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/000463
Other languages
English (en)
Other versions
WO2013111014A2 (fr
Inventor
Brian D. GULBRANSEN
Keith A. SHARKEY
Roger J. THOMPSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UTI LP
Original Assignee
UTI LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UTI LP filed Critical UTI LP
Publication of WO2013111014A2 publication Critical patent/WO2013111014A2/fr
Publication of WO2013111014A3 publication Critical patent/WO2013111014A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes de traitement de la perte neuronale dans des maladies intestinales inflammatoires (par exemple maladie de Crohn ou colite ulcéreuse), comprenant l'inhibition de la pannexine-1 chez un sujet.
PCT/IB2013/000463 2012-01-25 2013-01-25 Méthodes et compositions destinées au traitement de la perte neuronale dans des maladies intestinales inflammatoires Ceased WO2013111014A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261590530P 2012-01-25 2012-01-25
US61/590,530 2012-01-25

Publications (2)

Publication Number Publication Date
WO2013111014A2 WO2013111014A2 (fr) 2013-08-01
WO2013111014A3 true WO2013111014A3 (fr) 2013-10-31

Family

ID=48874023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/000463 Ceased WO2013111014A2 (fr) 2012-01-25 2013-01-25 Méthodes et compositions destinées au traitement de la perte neuronale dans des maladies intestinales inflammatoires

Country Status (1)

Country Link
WO (1) WO2013111014A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170157038A1 (en) * 2008-11-13 2017-06-08 Gholam A. Peyman Ophthalmic drug delivery method
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
WO2023143513A1 (fr) * 2022-01-26 2023-08-03 羽晓瑜 Composé polypeptidique et son utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEKENI, F. B. ET AL.: "Pannexin 1 channels mediate `find-me' signal release and membrane permeability during apoptosis", NATURE, vol. 467, October 2010 (2010-10-01), pages 863 - 867 *
GULBRANSEN, B. D. ET AL.: "Activation of neuronal P2X7 receptor-Pannexin-1 mediates death of enteric neurons during colitis", NATURE MED., vol. 18, October 2012 (2012-10-01), pages 600 - 604 *
SILVERMAN, W. R ET AL.: "The pannexin 1 channel activates the inflammasome in neurons and astrocyrtes", J. BIOL. CHEM., vol. 284, July 2009 (2009-07-01), pages 18143 - 18151 *
SRIDHARAN, M. ET AL.: "Pannexin 1 is the conduit for low oxygen tension- induced ATP release from human erythrocytes", AM. J. PHYSIOL. HEART CIRC. PHYSIOL., vol. 299, October 2010 (2010-10-01), pages H1146 - H1152 *

Also Published As

Publication number Publication date
WO2013111014A2 (fr) 2013-08-01

Similar Documents

Publication Publication Date Title
IL276153B (en) c1-inh preparations and methods for preventing and treating disorders associated with c1 esterase inhibitor deficiency
IL258846A (en) Nicotinamide for use in the treatment and prevention of optic neurodegenerative disorder
WO2016037157A3 (fr) Ciblage de l'activité capn9/capns2 en tant que stratégie thérapeutique pour le traitement de la différentiation des myofibroblastes et des pathologies associées
WO2013169704A3 (fr) Tétrahydronaphtyridine et composés bicycliques apparentés pour l'inhibition de l'activité rorgamma et le traitement d'une maladie
WO2014055996A3 (fr) Inhibiteurs de rho kinase
MX359327B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
WO2012149478A3 (fr) Agents utiles pour le traitement de l'ataxie de friedreich et autres maladies neurodégénératives
PL3242957T3 (pl) Kompozycje zawierające bakterie i sposoby ich wykorzystania do leczenia i/lub zapobiegania chorobom żołądkowo-jelitowym, metabolicznym i/lub innym
WO2012012278A3 (fr) Compositions et procédés pour le traitement de troubles pathologiques associés à gpr35 et/ou au complexe gpr35-herg
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
HK1249508A1 (zh) 氯喹和克立咪唑化合物用於治疗炎症和癌性病症的用途
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
WO2015143447A3 (fr) Méthodes de traitement de troubles neurologiques
EP2869819A4 (fr) Compositions, procédés et/ou dispositifs destinés à la prévention et/ou au traitement d'affections de type sécheresse oculaire
WO2015120372A3 (fr) Compositions et méthodes d'inhibition de ezh2 pour traiter des maladies cardiovasculaires
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
PL3442547T3 (pl) Lactobacillus reuteri mm4-1a do zastosowania w leczeniu lub profilaktyce zaburzeń ze spektrum autyzmu
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
SI3153511T1 (sl) Derivat 2-acilaminotiazola za uporabo v preprečevanju ali zdravljenju bolezni mehurja/urinarnega trakta
WO2010129347A3 (fr) Compositions et procédés pour le traitement de troubles mettant en jeu une apoptose de cellules épithéliales
EP3261446A4 (fr) Méthodes et compositions permettant le traitement ou la prévention de la maladie de parkinson
EP3310377A4 (fr) Méthode de traitement de la maladie de crohn
HK1214517A1 (zh) 4-羟基-2-甲基-5-(丙-2-亚基)环己-3-烯甲醛用於预防及治疗认知、神经退行性或神经元疾病
WO2013111014A3 (fr) Méthodes et compositions destinées au traitement de la perte neuronale dans des maladies intestinales inflammatoires
EP3142708A4 (fr) Test de diagnostic et de traitement/prévention de la maladie d'alzheimer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13741179

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13741179

Country of ref document: EP

Kind code of ref document: A2